Cypermethrin (CYP) is an important type II pyrethroid pesticide widely used to protect crops against pests and insect infestations. However, its toxicity is a risk to both human health and the surrounding environment. The present study was conducted to investigate the nephrotoxic effect and histopathological changes caused by Cypermethrin in the kidney tissues of adult Wistar rats. In this study, 30 Wistar rats were equally divided into three groups. G1, control animals; G2 and G3 treated with various sub lethal doses of CYP for 30 days as follows: G2, administered low dose (1/100 of LD50) of CYP; G3, administered high dose (1/50 of LD50) of CYP. The damage to different organelles of renal proximal and distal cells was observed using transmission electron microscopy. Histopathological damage in kidney samples was confirmed using morphological and histological measures. The results showed that CYP caused significant histopathological damage to the renal proximal and distal tubules of treated rats. Compared to control samples, CYP caused marked alterations in the dimensions of nucleus, ovoid and filamentous mitochondria of the treated cells. In conclusion, Cypermethrin is found to be toxic to mammals. It caused marked ultrastructural damage to the renal proximal and distal tubules of Wistar rats and the intensity of nephrotoxicity correlated with the dose of oral administration.

中文翻译：

---

氯氰菊酯对大鼠的肾毒性。组织病理学方面。

氯氰菊酯 (CYP) 是一种重要的 II 型拟除虫菊酯农药，广泛用于保护作物免受病虫害和虫害。然而，它的毒性对人类健康和周围环境都构成威胁。本研究旨在研究氯氰菊酯对成年 Wistar 大鼠肾组织的肾毒性作用和组织病理学变化。在这项研究中，30 只 Wistar 大鼠被平均分为三组。G1，对照动物；G2 和 G3 用各种亚致死剂量的 CYP 治疗 30 天如下： G2，给予低剂量（LD50 的 1/100）CYP；G3，给予高剂量（LD50 的 1/50）CYP。使用透射电子显微镜观察肾近端和远端细胞不同细胞器的损伤。使用形态学和组织学测量证实肾脏样本中的组织病理学损伤。结果表明，CYP对治疗大鼠的肾近端和远端肾小管造成显着的组织病理学损伤。与对照样品相比，CYP 导致处理细胞的细胞核、卵形和丝状线粒体的尺寸发生显着变化。总之，氯氰菊酯被发现对哺乳动物有毒。它对 Wistar 大鼠的肾近端和远端肾小管造成显着的超微结构损伤，肾毒性强度与口服剂量相关。CYP 导致处理细胞的细胞核、卵形和丝状线粒体的尺寸发生显着改变。总之，氯氰菊酯被发现对哺乳动物有毒。它对 Wistar 大鼠的肾近端和远端肾小管造成显着的超微结构损伤，肾毒性强度与口服剂量相关。CYP 导致处理细胞的细胞核、卵形和丝状线粒体的尺寸发生显着改变。总之，氯氰菊酯被发现对哺乳动物有毒。它对 Wistar 大鼠的肾近端和远端肾小管造成显着的超微结构损伤，肾毒性强度与口服剂量相关。